TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9761513

Group type: EXPERIMENTAL
Intervention: RenaGel (calcium- and aluminium-free phosphate binder), starting doses of one, two, or three 500-mg capsules three times per day with meals for 8 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RenaGel treatment
Number of subjects: 0
Study: 7800969

Group type: EXPERIMENTAL
Intervention: OM-85 BV (oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OM-85 BV (injection)
Number of subjects: 0
Study: 3364402

Group type: EXPERIMENTAL
Intervention: UV-A (320-400 nm) doses of 17.8 +/- 1.9 J/cm2 to the anterior side and 21.0 +/- 3.3 J/cm2 to the posterior side, with UV-B (280-320 nm) doses equivalent to 10% of UV-A doses.
Number of subjects: 24
Study: 31356810

Group type: EXPERIMENTAL
Intervention: 3.0-mm ultrathin bronchoscope (UTB)
Number of subjects: 356

Group type: COMPARATOR
Intervention: 4.0-mm thin bronchoscope
Number of subjects: 356
Study: 28532870

Group type: EXPERIMENTAL
Intervention: High repetitive, high dosage medical exercise therapy (MET), n=16
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low dosage exercise therapy (ET), n=17
Number of subjects: 33
Study: 25466662

Group type: EXPERIMENTAL
Intervention: Nutritional supplements (600 kcal, 20 g/d protein) and intensive rehabilitation program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nutritional supplements and rehabilitation program
Number of subjects: 200
Study: 23315099

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy with CA 19-9, CEA, CRP, LDH, and bilirubin levels assessed before treatment and during treatment (for CA 19-9 only)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Pre-treatment CA 19-9 levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Pre-treatment LDH levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Pre-treatment CEA levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Baseline CA 19-9 levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Baseline bilirubin levels
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Log [CA 19-9] as a continuous variable
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Log [bilirubin] and log [CRP]
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: CA 19-9 decline of ≥25% during the first two chemotherapy cycles
Number of subjects: 291
Study: 19744201

Group type: EXPERIMENTAL
Intervention: Chin bone augmentation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Chin bone covered by Bio-Gide® membrane
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bio-Oss® covered by Bio-Gide® membrane
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups (combined)
Number of subjects: 93
Study: 19581545

Group type: EXPERIMENTAL
Intervention: Project ALERT intervention (manualized classroom-based substance use prevention curriculum)
Number of subjects: 5883

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 5883
Study: 17094382

Group type: EXPERIMENTAL
Intervention: Sequential anthracycline-docetaxel regimen
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Participation in the ADEBAR study
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard chemotherapy with anthracyclines
Number of subjects: 98
Study: 15087630

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11702034

Group type: EXPERIMENTAL
Intervention: Intermittent moderate-intensity physical activity (10 min, three times a day, 5 days per week at 50-60% heart rate reserve)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No change in physical activity
Number of subjects: 18
Study: 9325503

Group type: EXPERIMENTAL
Intervention: Self‐declared spontaneous quitters
Number of subjects: 599

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 599
Study: 7934143

Group type: EXPERIMENTAL
Intervention: MM BM stromal cells
Number of subjects: 3

Group type: COMPARATOR
Intervention: MGUS BM stromal cells
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normal donor BM stromal cells
Number of subjects: 3
Study: 3135737

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (timing before or after 4 hours of AMI onset)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with patent arteries 90 minutes after therapy initiation
Number of subjects: 0
Study: 29129784

Group type: EXPERIMENTAL
Intervention: Removable partial dental prostheses (RPDP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both RPDP and SDA
Number of subjects: 89
Study: 27236703

Group type: EXPERIMENTAL
Intervention: Videoconferencing (VCF)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 93
Study: 26255173

Group type: EXPERIMENTAL
Intervention: 2-lesson intervention
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study: 24469138

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation sedation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no nitrous oxide/oxygen inhalation sedation)
Number of subjects: 72
Study: 21835201

Group type: EXPERIMENTAL
Intervention: Skeleton projection-based approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uniform (DC) offset between two groups
Number of subjects: 0
Study: 18307586

Group type: EXPERIMENTAL
Intervention: CBT + SSRI
Number of subjects: 150

Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 150

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 150
Study: 22311406

Group type: EXPERIMENTAL
Intervention: Feitai Capsule (1.2 g/capsule, 4 capsules, 3 times a day for 3 weeks, followed by 1 week off, continued for at least 3 more cycles, totaling 12 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (regular follow-up and evaluation every 8 weeks until PD)
Number of subjects: 62
Study: 15960643

Group type: EXPERIMENTAL
Intervention: 0.3 ml.kg(‐1) bupivacaine 0.25% plus 1 microg.kg(‐1) clonidine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% alone
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 12580705

Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine estrogen) 0.625 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine estrogen) 1.25 mg/d
Number of subjects: 120
Study: 10204895

Group type: EXPERIMENTAL
Intervention: Spinocath
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralong
Number of subjects: 60
Study: 7779441

Group type: EXPERIMENTAL
Intervention: Ipecacuanha-induced emesis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study: 2077584

Group type: EXPERIMENTAL
Intervention: PPD 10 TU
Number of subjects: 322

Group type: COMPARATOR
Intervention: PPD 2 TU
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Booster effect from second tuberculin test
Number of subjects: 322
Study: 312366

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg added to each liter of cardioplegic solution)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone added)
Number of subjects: 22
Study: 12006932

Group type: EXPERIMENTAL
Intervention: HspE7 (500 microg monthly for 3 months)
Number of subjects: 22
Study: 31256250

Group type: EXPERIMENTAL
Intervention: Accelerated Skills Acquisition Protocol (ASAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional Training Protocol (CTP)
Number of subjects: 16
Study: 29481992

Group type: EXPERIMENTAL
Intervention: Silicate-based wound dressing (DermFactor®) combined with conventional dressing therapy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Conventional dressing therapy
Number of subjects: 328
Study: 26802812

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (omega-3 PUFAs) for 6 weeks
Number of subjects: 16
Study: 25539547

Group type: EXPERIMENTAL
Intervention: Negative-calorie diet (NCD) with exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-calorie diet (LCD) with exercise
Number of subjects: 37
Study: 22365373

Group type: EXPERIMENTAL
Intervention: Meniett low-pressure generator
Number of subjects: 68
Study: 20370447

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unfractioned Heparin (UFH)
Number of subjects: 40
Study: 18413671

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16634346

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Trunk Control Test
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Motricity Index of arm and leg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Brunnstrom Fugl‐Meyer stage of leg motor recovery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Type of intervention
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Weekly re-evaluation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Independent gait (FAC > or = 4)
Number of subjects: 101
Study: 14558379

Group type: EXPERIMENTAL
Intervention: Occlusal management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 11054359

Group type: EXPERIMENTAL
Intervention: Vancomycin (1,000 mg IV, 12 hours before procedure)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Cefazolin (1,000 mg IV, 3 hours before procedure)
Number of subjects: 221

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 221
Study: 8844478

Group type: EXPERIMENTAL
Intervention: 0.3 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study: 1626962

Group type: EXPERIMENTAL
Intervention: Controlled localized heating at 50 degrees C for 30 to 60 seconds
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 29
Study: 6439714

Group type: EXPERIMENTAL
Intervention: Specific prompt and monetary incentives
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Specific prompt and increased public health clinic access
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Specific prompt
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: General prompt
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 1133

Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 1133
Study: 31372804

Group type: EXPERIMENTAL
Intervention: RPE-clamp runs at RPEGET
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RPE-clamp runs at RPEGET+15%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 29712564

Group type: EXPERIMENTAL
Intervention: PARTNER model intervention with tailored online training and electronic medical record support for GPs, including referral to the PARTNER Care Support Team (CST), provision of OA educational materials, a leg muscle strengthening program, and access to a weight-loss program.
Number of subjects: 572

Group type: COMPARATOR
Intervention: Usual care provided by control group GPs without additional training.
Number of subjects: 572
Study: 26620733

Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) using quad-helix appliance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) using Hyrax expander
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of SME and RME
Number of subjects: 50
Study: 25150285

Group type: EXPERIMENTAL
Intervention: Directional steering with a 32-contact electrode
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional spherical stimulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Monopolar mode with a commercial electrode
Number of subjects: 8
Study: 21414131

Group type: EXPERIMENTAL
Intervention: Titanium-13Zirconium (TiZr) implants
Number of subjects: 91

Group type: COMPARATOR
Intervention: Titanium Grade IV implants
Number of subjects: 91
Study: 20205166

Group type: EXPERIMENTAL
Intervention: Calcium intake of 629 to 1835 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calcium intake of 648 mg/day (boys)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calcium intake of 666 mg/day (girls)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calcium absorption and bone turnover rates measured using double-stable calcium isotope kinetic analysis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1100 mg/day (boys)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calcium intake of 970 mg/day (girls)
Number of subjects: 29
Study: 17912118

Group type: EXPERIMENTAL
Intervention: Poly(L‐lactide‐co‐glycolide) osteofixation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Titanium osteofixation
Number of subjects: 45
Study: 16047154

Group type: EXPERIMENTAL
Intervention: Verum (homeopathic treatment) for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Long-term follow-up after treatment
Number of subjects: 62
Study: 12452075

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) with atropine (0.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenobarbital sodium (2 mg/kg) with atropine
Number of subjects: 30
Study: 10077182

Group type: EXPERIMENTAL
Intervention: Behavioral and social issues investigation
Number of subjects: 0
Study: 7474770

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (CEDA) using implantable catheterization system 'Periplant'
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (CEDA) using nonimplantable 'Periflex++'
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (33 patients)
Number of subjects: 33
Study: 2266671

Group type: EXPERIMENTAL
Intervention: Insulin with glucose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined regimen of insulin with glucose and albuterol
Number of subjects: 12
Study: 6102284

Group type: EXPERIMENTAL
Intervention: 200,000 IU oil-miscible vitamin A orally
Number of subjects: 114

Group type: COMPARATOR
Intervention: 100,000 IU water-miscible vitamin A intramuscularly
Number of subjects: 114
Study: 31759243

Group type: EXPERIMENTAL
Intervention: Flipped classroom intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 200
Study: 31392484

Group type: EXPERIMENTAL
Intervention: Microscopic subinguinal varicocelectomy with open-mouth pressure to drain stagnant venous blood
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine microscopic subinguinal varicocelectomy
Number of subjects: 100
Study: 27740972

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 2181
Study: 26518046

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 272

Group type: COMPARATOR
Intervention: Formula-feeding
Number of subjects: 272
Study: 24452729

Group type: EXPERIMENTAL
Intervention: BP-BES (biolimus-eluting stents with biodegradable polymer)
Number of subjects: 34
Study: 22421627

Group type: EXPERIMENTAL
Intervention: Bilateral training (BT) for 20 minutes on weekdays over a 6-week period
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control training involving the contralesional arm only
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bilateral training (BT) for younger participants (age≤68y)
Number of subjects: 106
Study: 20644183

Group type: EXPERIMENTAL
Intervention: Promotional and educational intervention program (lecture session, e-mail literature, reminders, personal approach)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Promotional and educational intervention program
Number of subjects: 344
Study: 17716826

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 U once weekly, starting 7-10 days before radiotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (no Epo)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 148
Study: 15818603

Group type: EXPERIMENTAL
Intervention: Mental Health Court (MHC) clients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study: 12040280

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (induction chemotherapy with cisplatin, etoposide, and vinblastine followed by radiotherapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy
Number of subjects: 101
Study: 10885909

Group type: EXPERIMENTAL
Intervention: Paclitaxel + cisplatin (TAXCIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teniposide + cisplatin (TENCIS)
Number of subjects: 0
Study: 7580077

Group type: EXPERIMENTAL
Intervention: Reagent strip testing of urine specimens
Number of subjects: 0
Study: 1962593

Group type: EXPERIMENTAL
Intervention: Droloxifene (new antiestrogenic drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Droloxifene (film-coated tablet, tablet, and standard solution)
Number of subjects: 0
Study: 6759056

Group type: EXPERIMENTAL
Intervention: 600 mg tiaprofenic acid daily for 1 week
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 140
Study: 31739708

Group type: EXPERIMENTAL
Intervention: tDCS (1-mA anodal stimulation for 20 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 10
Study: 29637543

Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 1635
Study: 26844514

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training at 20 Hz, 3 times per week for 5 min each session
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Visual feedback-deprived plus WBV (VFDWBV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training at 20 Hz
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (0 Hz, eyes open)
Number of subjects: 45
Study: 24807340

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 160

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 160
Study: 21336631

Group type: EXPERIMENTAL
Intervention: RelyX Unicem combined with Gluma Desensitizer (RXU‐G)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: G‐Cem combined with Gluma Desensitizer (GCM‐G)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Panavia21 (PAN)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Panavia21 combined with Gluma Desensitizer (PAN‐G)
Number of subjects: 144
Study: 19233485

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 microg once daily, n=166
Number of subjects: 255

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 168 microg, n=85
Number of subjects: 255
Study: 17846891

Group type: EXPERIMENTAL
Intervention: Culturally adapted HIV prevention program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study: 15178656

Group type: EXPERIMENTAL
Intervention: 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 80
Study: 11965505

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg) once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Number of subjects: 34
Study: 11153770

Group type: EXPERIMENTAL
Intervention: Right ventricular myocardial involvement
Number of subjects: 491

Group type: COMPARATOR
Intervention: No right ventricular myocardial involvement
Number of subjects: 491

Group type: COMPARATOR
Intervention: Anterior myocardial infarction
Number of subjects: 491

Group type: COMPARATOR
Intervention: Inferior myocardial infarction
Number of subjects: 491
Study: 9781722

Group type: EXPERIMENTAL
Intervention: Surfactant (30 mg/kg) administered by intrabronchial instillation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no surfactant instilled)
Number of subjects: 11
Study: 8162664

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg four times a day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2901612

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical stimulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: No electrical stimulation (control group)
Number of subjects: 21
Study: 8345000

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin, tobramycin, netilmicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no aminoglycosides)
Number of subjects: 0
Study: 362821

Group type: EXPERIMENTAL
Intervention: Formulation A (Tegretol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Formulation B (Neurotol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Experimental preparations C and D
Number of subjects: 4
Study: 31100038

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg (NIVO3)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg (NIVO3+IPI1)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg (NIVO1+IPI3)
Number of subjects: 274